New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
10:04 EDTJNJ, IART, ZMH, SNN, WMGI, SYK, TRNXVolume trends from CCJR meeting positive for Zimmer, says Piper Jaffray
Piper Jaffray said it has more confidence in improving volume trends in the orthopedic market following its attendance at the Current Concepts in Joint Replacement meeting, which it views as particularly positive for Zimmer (ZMH). The firm also said the trends and expectations pointed to at the meeting were positive, but to a lesser extent, for Tornier (TRNX), Wright Medical (WMGI), Integra LifeSciences (IART), Stryker (SYK), Smith & Nephew (SNN) and Johnson & Johnson (JNJ).
News For ZMH;TRNX;WMGI;IART;SYK;SNN;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 26, 2014
07:21 EDTSNN, SYKSmith & Nephew could attract GBP14 per share takeover bid, says Bernstein
Subscribe for More Information
November 24, 2014
11:25 EDTSYK, ZMH, SNN, JNJStryker, Smith & Nephew rise after reports of renewed bid
Subscribe for More Information
09:26 EDTJNJFDA updates warning on laparoscopic power morcellators to treat uterine fibroids
The FDA announced it is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids. In an updated safety communication, originally issued in April, the FDA warns against using laparoscopic power morcellators in the removal of the uterus or fibroids in the vast majority of women. In an Immediately in Effect guidance, the FDA is also recommending that manufacturers of laparoscopic power morcellators include in their product labeling specific safety statements in the form of a boxed warning and two contraindications. Johnson & Johnson (JNJ), the largest manufacturer of morcellators, stopped selling the gynecological surgical tool in April and in August told customers to return any devices in their inventory. Intuitive Surgical's (ISRG) da Vinci surgical system can be used with tissue morcellators in such surgical procedures.
09:05 EDTSYK, SNNStryker weighing renewed Smith & Nephew bid, Bloomberg reports
Subscribe for More Information
08:46 EDTSNN, SYKStryker weighing renewed Smith & Nephew bid, Bloomberg reports
Subscribe for More Information
07:46 EDTSNN, SYKPfizer seen set to move on from AstraZeneca as restrictions lift, Telegraph says
Subscribe for More Information
November 21, 2014
09:27 EDTSNN, SYKRumors of Smith & Nephew bid from Stryker intensify, Daily Mail says
Shares of Smith & Nephew (SNN) rallied in U.K. trading amid "intensified" rumors that Stryker (SYK) will make a GBP 13B plus bid for its rival when its Takeover Panel restrictions are removed at month end, according to The Daily Mail's "This is Money." Reference Link
November 20, 2014
10:33 EDTZMHHigh option volume stocks
High option volume stocks: KBR LM PRGO CHRW DG ZMH LGF ZTS OSIR REGI
November 19, 2014
09:11 EDTZMHZimmer reports Synovasure PJI test earns certification
Subscribe for More Information
09:04 EDTJNJJohnson & Johnson submits NDA for three-month paliperidone palmitate
Janssen Research & Development, a Johnson & Johnson company, announced the submission of a New Drug Application, or NDA, for three-month atypical antipsychotic paliperidone palmitate to the FDA. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. If approved, it will be the first and only long-acting atypical antipsychotic that has a four times a year dosing schedule.
07:39 EDTSNNSWM to acquire assets from Smith & Nephew, terms not disclosed
Subscribe for More Information
07:11 EDTSNNSanofi drawing up list of CEO candidates to repalce Viehbacher, Reuters reports
Sanofi's (SNY) board is in the process of drawing up a short list of CEO candidates to replace Chris Viehbacher, sources tell Reuters. Jean-Rene Fourtou, a Sanofi director and the honorary chairman of media group Vivendi (VIVHY), has been selected to lead the appointments and governance committee that will select the next CEO. Smith & Nephew (SNN) CEO Olivier Bohuon, AstraZeneca (AZN) CEO Pascal Soriot and former Wyeth CEO Bernard Poussot have been rumored to be potential contenders for the CEO position. Reference Link
06:30 EDTJNJJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
November 18, 2014
15:04 EDTSNNSmith & Nephew management to meet with Jefferies
Subscribe for More Information
09:56 EDTWMGIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:30 EDTZMHZimmer agrees with EC to extend deal review deadline by 'limited number of days'
Zimmer Holdings announced that it has agreed with the European Commission to extend the deadline for the EC's review of Zimmer's proposed acquisition of Biomet by a "limited number of days" in order to provide the EC with certain additional information. Under the previous timeline, the EC had until March 11, 2015 to make a final decision on the proposed transaction. As a result of this extension, the deadline for the EC's final decision will be extended by the limited amount of additional time that Zimmer has agreed to provide to the EC. "Deadline extensions are not uncommon in such in-depth investigations. Zimmer has been working closely with the regulatory authorities to facilitate their review of the pending transaction and is encouraged by the substantial progress that has been made to date in connection with the overall regulatory process. Zimmer continues to expect to close the transaction in the first quarter of 2015," the company said.
05:35 EDTTRNX, WMGIWright Medical upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Wright Medical (WMGI) to Overweight citing the recent underperformance of shares and its positive view of the Tornier (TRNX) acquisition. The firm raised its price target for shares to $37 from $36.
November 17, 2014
07:16 EDTJNJMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
16:21 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
14:53 EDTJNJCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use